生产2’-脱氧尿苷的基因工程菌及其构建方法和应用
By genetically engineering Escherichia coli W3110 and optimizing its metabolic pathway, the problems of high cost of chemical synthesis and low yield of microbial fermentation were solved, enabling safe and low-cost industrial production of 2'-deoxyuridine.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 新疆瑞诺生物科技有限公司
- Filing Date
- 2024-11-25
- Publication Date
- 2026-07-17
AI Technical Summary
Existing chemical synthesis methods for producing 2'-deoxyuridine are costly and unsuitable for large-scale industrial production, while microbial fermentation methods suffer from low strain yields.
By genetically engineering Escherichia coli W3110, deoxyuridine kinase tdk was knocked out and T7 RNA polymerase was integrated. Aspartate transaminase aspC, glutamine synthase glnA, 5'-deoxynucleotidase yfbR and uridine kinase pyrH were overexpressed, and ribonucleoside diphosphate reductase nrdBCA and CTP synthase pyrG* were heterologously introduced to optimize the metabolic pathway and enhance 2'-deoxyuridine synthesis.
The constructed genetically engineered strain has good genetic stability, is safe in the production process, reduces production costs, and is suitable for industrial production of 2'-deoxyuridine.
Smart Images
Figure CN119432703B_ABST